7月20日，科伦博泰生物盘中上涨3.41%，报514.0港元，成交额9828.4万港元。
消息面上，此前公司核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性NSCLC的III期研究达主要终点后，股价经历连续回调。近日多家国际投行密集上调目标价：摩根大通将目标价由535港元大幅上调至648港元，维持"增持"评级；高盛将目标价上调至582.95港元，维持"买入"评级，并将Lung06成功率由81%上调至90%。投行一致看好公司作为全球ADC药企的商业化前景，为股价提供估值支撑。
板块层面，今日生物科技板块集体反弹，荣昌生物涨5.97%、康方生物涨4.13%、三生制药涨3.59%、信达生物涨3.54%、百济神州涨3.39%，板块情绪回暖带动个股企稳回升。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.